2675 results about "Coronavirus" patented technology

The invention discloses a monoclonal antibody for identifying canine distemper virus H protein, a detection test strip and application. The monoclonal antibody comprises a monoclonal antibody 5-8H or a monoclonal antibody 9-7B and has high specificity and sensitivity, the two antibodies can recognize different epitopes, and a detection test strip can be prepared through a double-antibody sandwich method. Tests prove that the monoclonal antibody provided by the invention has no obvious cross reaction on canine parvovirus, canine adenovirus, canine coronavirus and canine parainfluenza virus in preparation of a colloidal gold test strip for detecting the canine distemper virus, and has good specificity and higher sensitivity.

The invention provides methods and means for the inhibition or neutralisation of death receptor / death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and / or the Toll-like receptor family, and / or NOD-like receptor and / or of the signalling induced via these receptors, preferably in combination with each other and / or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

The invention discloses a fatty acid modified coronavirus antigen and application thereof, and belongs to the field of biological medicine. The fatty acid modified coronavirus antigen contains fatty acid modified N-terminal cysteine (Cys) and a coronavirus antigen, and can contain a connecting structural domain; the coronavirus antigen is a coronavirus spike protein (S protein) receptor binding domain (RBD). The fatty acid modified coronavirus S protein RBD can be self-polymerized into nanoparticles, and compared with the RBD which is not subjected to fatty acid modification, the antigen can induce faster and higher humoral immunity through injection immunity, can induce mucosal immunity and humoral immunity through respiratory tract atomization immunity, and is a candidate mucosal vaccine with potential medical value.

The invention relates to the technical field of gene engineering, in particular to a nucleic acid composition, a kit and a detection method for simultaneously and rapidly detecting 16 respiratory tract pathogens. The method specifically comprises the following steps: detecting influenza A virus, influenza B virus, novel coronavirus (ORF1ab gene, N gene), haemophilus influenzae, universal human parainfluenza virus, respiratory syncytial virus, human metapneumovirus, enterovirus, mycoplasma pneumoniae, group A streptococcus, bordetella pertussis, common coronavirus, rhinovirus, bocavirus and adenovirus; a forward primer, a reverse primer and a specific fluorescent probe of streptococcus pneumoniae. Through the PCR reaction, whether respiratory tract pathogens exist or not can be rapidly detected from a specimen at the same time, typing identification of 16 respiratory tract pathogens is carried out at the same time, and compared with a single fluorescent quantitative PCR method, the method is more convenient and rapid, and the cost is lower.

The invention provides a nucleic acid composition for respiratory tract pathogen detection and application thereof, and relates to the technical field of biology. The invention provides a nucleic acid detection composition which has high specificity and can be used for detecting various respiratory pathogens. The composition can be used for detecting influenza B virus, influenza A virus H1N1, influenza A virus H3N2, novel coronavirus N gene, novel coronavirus O gene, respiratory syncytial virus, I-type parainfluenza virus, II-type parainfluenza virus, III-type parainfluenza virus, IV-type parainfluenza virus, rhinovirus, adenovirus, haemophilus influenzae, and the like. The kit has 15 pathogens including streptococcus pneumoniae and staphylococcus aureus, the lower detection limit can be as low as 20 copies / reaction, and the kit plays an important role in rapid detection of respiratory tract pathogens.

The present disclosure identifies a set of T cell and B cell epitopes derived from Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) and their use in designing vaccines against SARS-CoV-2. A method for eliciting an immune response for prophylactic or therapeutic application using the T cell and / or B cell epitopes is described. Further disclosed are SARS-CoV-2-specific polypeptides, nucleic acids, host cells, and corresponding compositions for eliciting or measuring an immune response to SARS-CoV-2 and / or other coronaviruses.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which mainly utilizes a multiple fluorescent PCR analysis method to detect related pathogens, so as to simultaneously realize detection of coronavirus, bordetella pertussis, group A streptococcus, parainfluenza virus, streptococcus pneumoniae, haemophilus influenzae and group B streptococcus in a single-tube reaction system. Or detecting and distinguishing at least four of chlamydia pneumoniae. Meanwhile, the detection sensitivity of the composition is higher and reaches 500 copies / mL, and the detection is more accurate.

The invention provides a primer probe combination and a kit for detecting porcine diarrhea related viruses, and belongs to the technical field of virus detection. The combination comprises specific primers and fluorescent probes aiming at a porcine epidemic diarrhea virus (PEDV), a porcine group A rotavirus (PoRV-A), a porcine transmissible gastroenteritis virus (TGEV) and a porcine delta coronavirus (PDCoV). The primer probe combination disclosed by the invention can be used for simultaneously detecting and identifying the four viruses mainly causing porcine diarrhea in one PCR reaction, and has the characteristics of high specificity, high sensitivity, simplicity and convenience in operation, rapidness and high efficiency. Therefore, according to the invention, rapid and accurate detection of porcine diarrhea related viruses can be realized, and disease prevention and control and epidemiological investigation of pig farms can be effectively supported.

The invention discloses a specific antibody capable of combining with a coronavirus SARS-CoV-2 and an SARS-CoV spike protein (SARS-CoV spike protein), and an application of the specific antibody capable of combining with the coronavirus SARS-CoV-2 and the SARS-CoV spike protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention comprises CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV spike protein, and has a relatively strong binding reaction with spike protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method.

The invention relates to the field of molecular diagnosis, in particular to an RPA-Cas12a one-step detection system and application thereof. The invention finds that heparin sodium has cleavage activity for inhibiting LbCas12a, and develops a one-step nucleic acid detection method compatible with RPA amplification and Cas12 detection based on the inhibition effect. The detection limit of the method reaches 0.6 (copy / microliter), and the method can be expanded to other two Cas12 subtype proteins, namely AsCas12a and AapCas12b. In the detection of monkey pox virus, influenza A virus and new coronavirus as examples, compared with quantitative PCR, the detection sensitivity and specificity of the method both reach 95% or above. The CRISPR one-step nucleic acid detection method has the advantages of high sensitivity and specificity, short detection time and the like, and the potential nucleic acid aerosol pollution risk of a traditional two-step nucleic acid detection method is removed.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.

The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

The invention relates to a novel coronavirus recombinant chimeric antigen, a related product thereof, a preparation method and application of the novel coronavirus recombinant chimeric antigen in preparation of a novel coronavirus vaccine. The recombinant chimeric antigen is a recombinant new coronavirus Omicron variant RBD trimer antigen, various types of vaccines based on the recombinant chimeric antigen can induce strong immune response aiming at various subtype variants (including BA.1, BA.2, BA.5, XBB, EG.5, BA.2. 86, JN.1, KP.2 and the like) of the new coronavirus Omicron, and particularly, compared with a protein vaccine of the recombinant chimeric antigen, the recombinant chimeric antigen can induce strong immune response. The mRNA vaccine based on the recombinant chimeric antigen can induce an organism to generate obviously higher RBD specific binding antibody level and neutralizing antibody level, so that the mRNA vaccine can be used as a candidate of a new generation of new coronavirus vaccines, and has potential clinical application value and prospect.

The invention discloses a primer group and a kit for simultaneously detecting nucleic acids of various respiratory pathogens based on twenty-six PCR (Polymerase Chain Reaction). The kit comprises primer pool freeze-dried powder of influenza A virus (FluA), influenza B virus (FluB), respiratory syncytial virus (RSV), human parainfluenza virus (hPIV), mycoplasma pneumoniae (MP), novel coronavirus (SARS-CoV-2), human respiratory adenovirus (HADV), human respiratory nose / enterovirus (HRV / HEV), bordetella pertussis (BP), human coronavirus (HCoV), human bocavirus (HBoV) and chlamydia pneumoniae (CP), PCR (polymerase chain reaction) freeze-dried powder and a buffer solution. According to the kit, primer system optimization is carried out on various pathogens, brand new primers and probe pools are designed, clinical sensitivity and specificity can be achieved, and meanwhile, the kit is matched with a fully-closed full-automatic detection card box integrating sample treatment and amplification and is suitable for rapid detection of respiratory tract pathogens.

The invention discloses a specific antibody MR-34 for targeting a coronavirus MERS-CoV spike protein RBD (Radial Basis Disease). The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, and can be specifically combined with an MERS-CoV spike protein RBD structural domain. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an MERS-CoV infection detection method.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention relates to a PLpro protease small-molecule inhibitor for treating or preventing coronavirus infection and application of the PLpro protease small-molecule inhibitor. Specifically, the invention relates to a compound shown as a formula (I) or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, and the use thereof in the preparation of a medicament for treating or preventing coronavirus infection or diseases or symptoms caused by coronavirus.

The invention provides a subunit fusion protein RBD-Fc on the surface of a porcine D-type coronavirus and a preparation method and application thereof, the preparation method comprises the following steps: 1) cloning a gene sequence as shown in SEQ ID NO.5 into a eukaryotic expression vector to obtain a recombinant plasmid containing a fusion protein RBD-Fc coding gene; (2) transfecting a recombinant plasmid containing the fusion protein RBD-Fc coding gene into an expression cell; 3) culturing, screening and domesticating the expression cells in the step 2) to obtain a highly expressed cell strain; and 4) fermenting and culturing the cell strain in the step 3), and purifying to obtain the subunit fusion protein RBD-Fc. According to the present invention, the RBD-Fc can be subjected to mass soluble expression, the protein is stable, the problems that the porcine D-coronavirus surface S protein cannot be subjected to large-scale expression and the like in the prior art are solved, the preparation method is simple, and the cost is low.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention belongs to the technical field of biological pharmacy, and particularly relates to influenza virus-like particles for chimeric expression of new coronavirus RBD protein as well as a preparation method and application of the influenza virus-like particles. The virus-like particle is prepared by embedding fusion protein on the surface of influenza virus M1, and the fusion protein comprises an HA2 segment of HA protein of influenza virus, an extracellular functional region of M2e matrix protein, a conserved region short peptide of nucleoprotein, and RBD tandem protein with mutated five sites of 417, 452, 478, 484 and 501 of new coronavirus; the virus-like particles can be used for preventing specific influenza and new crowns; the preparation method of the virus-like particles is simple and low in cost, the virus-like particles are good in immunogenicity and cross protectiveness, the preparation requirements of large-scale influenza vaccines can be met, the biological safety is high, and the immunity of an organism to various influenza viruses and new coronal viruses can be stimulated.

The application provides a virus combined detection immunochromatography test paper, a detection pen and a detection product, and relates to the technical field of immunochromatography test paper. The virus combined detection immunochromatography test paper can detect the novel coronavirus, the influenza A virus and the influenza B virus in a three-in-one manner. The sample binding pad of the immunochromatography test paper is coated with labeled antibodies, including a first influenza A virus antibody, a first influenza B virus antibody, a first novel coronavirus antibody and a first human internal reference protein antibody, and each labeled antibody is labeled with a different color of label. The immunochromatography test paper adopts a double-antibody sandwich principle, and the second influenza A virus antibody, the second influenza B virus antibody and the second novel coronavirus antibody are coated on different detection lines in the detection area. The immunochromatography test paper and the detection pen solve the problems of complex operation and difficult interpretation of the three-in-one detection product of the novel coronavirus, the influenza A virus and the influenza B virus in the prior art.

The invention discloses a system for evaluating an ADE effect and application thereof. The system comprises: (i) and (iii); (ii) and (iii); or (i), (ii) and (iii); (i) is a Middle East Respiratory Syndrome Coronavirus pseudovirus, (ii) is an antibody that targets the receptor binding domain of the Middle East Respiratory Syndrome Coronavirus, and (iii) is a cell that overexpresses CD32B; the cells are CHO cells; the pseudovirus contains a Spike protein coding gene of the Middle East Respiratory Syndrome Coronavirus. According to the invention, the ADE activity of the Middle East respiratory coronavirus antibody is identified in vitro by using MERS-CoV pseudovirus and cells for exogenous expression of CD32B. Compared with an immune cell Raji and an ADE evaluation system based on exogenous expression CD32A cells, the system provided by the invention is more sensitive, and is a potential system for evaluating the ADE effect of the Middle East respiratory coronavirus.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention discloses a novel isoxazolopyrimidine derivative with anti-new coronavirus activity as well as a preparation method and application of the novel isoxazolopyrimidine derivative. The isoxazolopyrimidine compound provided by the invention has a good inhibition effect on SARS-CoV-2, and relates to the compound shown in the general formula (I), and pharmaceutically acceptable salts and solvent compounds thereof have a good inhibition effect on new coronavirus, and can be used for preparing antiviral drugs related to the new coronavirus for prevention, treatment or adjuvant treatment. # imgabs0 #

The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment.

The present disclosure provides for devices and systems for detecting biological agents (e.g., virus such as coronavirus) using nanotriangles having a capture agent. The present disclosure also includes methods of detecting the presence and amount of the biological agent in a sample, such as saliva, blood, or urine. In addition, the present disclosure provides for a detecting module and a method of making the detecting module, where the detecting module includes the nanotriangles having the capture agent bonded thereto that has an affinity for the biological agent.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.